Consensus iTeos Therapeutics, Inc.

Equities

ITOS

US46565G1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
17.44 ^USD	+43.07%		+49.57%	+59.27%

May. 10	Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating	MT
May. 10	ITeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump	MT

Evolution of the average Target Price on iTeos Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4d.YTGXUEz1p-iv68A8U2WO4Qs8Qc7bO6zkGKWdJ5ONDGE.PmHmBC7D1IbAxvZoYST0k3lyEqKYXMWsaO2tVqX3ZkwoZ7oHJoDVieyDiQ~725fd0716de9e4c6935af05189ec9eb4

Analyst Recommendations on iTeos Therapeutics, Inc.

Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating	May. 10	MT
JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating	Mar. 12	MT
Wedbush Adjusts iTeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating	Mar. 06	MT
JPMorgan Cuts Price Target on iTeos Therapeutics to $29 From $32, Maintains Overweight Rating	Nov. 13	MT
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $44 From $54, Maintains Buy Rating	23-08-09	MT
JPMorgan Chase Adjusts Price Target on iTeos Therapeutics to $32 From $34, Maintains Overweight Rating	23-03-16	MT
Wedbush Lowers iTeos Therapeutics' Price Target to $33 From $45 Following Model Update; Keeps Outperform Rating	23-03-16	MT
Wedbush Lifts Price Target on iTeos Therapeutics to $45 From $42, Keeps Outperform Rating	22-08-11	MT
Wedbush Adjusts Price Target on ITeos Therapeutics to $42 From $49, Citing EOS-448 Launch Estimates; Outperform Rating Kept	22-05-13	MT
Piper Sandler Adjusts Price Target on ITeos Therapeutics to $34 From $42, Reiterates Overweight Rating	22-05-12	MT
Wedbush Removes Outperform-Rated ITeos Therapeutics From Best Ideas List; Price Target is $49	22-05-06	MT
Wedbush Lifts ITeos Therapeutics' Price Target to $49 From $48; Outperform Rating Kept	21-12-16	MT
HC Wainwright Adjusts iTeos Therapeutics' Price Target to $54 from $37, Keeps Buy Rating	21-12-13	MT
Piper Sandler Adjusts iTeos Therapeutics' Price Target to $42 From $50, Reiterates Overweight Rating	21-11-11	MT
Wedbush Lowers ITeos Therapeutics' Price Target to $48 From $52; Outperform Rating Kept	21-11-11	MT
ITEOS THERAPEUTICS : Wedbush Lifts ITeos Therapeutics' Price Target to $52 From $50, Keeps Outperform Rating	21-08-13	MT
ITEOS THERAPEUTICS : Wedbush Adjusts ITeos Therapeutics' Price Target to $50 From $52, Keeps Outperform Rating	21-06-15	MT
ITEOS THERAPEUTICS : SVB Leerink Adjusts Price Target on ITeos Therapeutics to $45 From $60, Maintains Outperform Rating	21-05-19	MT
ITEOS THERAPEUTICS : HC Wainwright Starts ITeos Therapeutics at Buy With $37 Price Target	21-05-05	MT
ITEOS THERAPEUTICS : SVB Leerink Adjusts Price Target on iTeos Therapeutics to $60 From $37, Maintains Outperform Rating	21-04-06	MT
ITEOS THERAPEUTICS : Wedbush Raises Price Target for iTeos Therapeutics Ahead of Potentially Upbeat EOS-448 Data, Maintains Outperform Rating	21-03-25	MT
ITEOS THERAPEUTICS : Wedbush Adjusts Price Target on ITeos Therapeutics to $46 From $45, Keeps Outperform Rating	20-11-13	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.44 USD

Average target price

34.4 USD

Spread / Average Target

+97.25%

High Price Target

47 USD

Spread / Highest target

+169.50%

Low Price Target

18 USD

Spread / Lowest Target

+3.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering iTeos Therapeutics, Inc.

Wedbush
JPMorgan Chase
HC Wainwright
Piper Sandler
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar